Cumulative exposure to lead and cognition in persons with Parkinson's disease

Movement Disorders

Volumn 28, Issue 2, 2013, Pages 176-182

  Weuve, Jennifer ^a,b   Press, Daniel Z ^c   Grodstein, Francine ^b,d   Wright, Robert O ^b,d,e   Hu, Howard ^f   Weisskopf, Marc G ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cognitive function; Lead exposure; Parkinson's disease

Indexed keywords

LEAD;

ADULT; AGED; ARTICLE; ATTENTION; CHEMICAL ANALYSIS; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PATELLA; PERFORMANCE; PRIORITY JOURNAL; TELEPHONE; TIBIA; VALIDATION STUDY; WORKING MEMORY; X RAY FLUORESCENCE;

AGE OF ONSET; AGED; AGED, 80 AND OVER; BONE AND BONES; COGNITION; EDUCATIONAL STATUS; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; LEAD; LEAD POISONING, NERVOUS SYSTEM; LEARNING; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; SMOKING; SPECTROMETRY, X-RAY EMISSION; TELEPHONE; TRAIL MAKING TEST; VERBAL BEHAVIOR;

EID: 84874211478     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25247     Document Type: Article

References (41)

1. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010;289:18-22.
2. Caviness JN, Lue L, Adler CH, Walker DG. Parkinson's disease dementia and potential therapeutic strategies. CNS Neurosci Ther 2011;17:32-44.
3. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14:866-874.
4. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-942.
5. Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson disease. Arch Neurol 1997;54:260-264.
6. Buchman AS, Leurgans SE, Boyle PA, Schneider JA, Arnold SE, Bennett DA. Combinations of motor measures more strongly predict adverse health outcomes in old age: the rush memory and aging project, a community-based cohort study. BMC Med 2011;9:42.
7. Murray AM, Bennett DA, Mendes de Leon CF, Beckett LA, Evans DA. A longitudinal study of parkinsonism and disability in a community population of older people. J Gerontol A Biol Sci Med Sci 2004;59:864-870.
8. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Burden of parkinsonism: a population-based study. Mov Disord 2003;18:313-319.
9. Shih RA, Hu H, Weisskopf MG, Schwartz BS. Cumulative lead dose and cognitive function in adults: a review of studies that measured both blood lead and bone lead. Environ Health Perspect 2007;115:483-492.
10. Weuve J, Korrick SA, Weisskopf MA, et al. Cumulative exposure to lead in relation to cognitive function in older women. Environ Health Perspect 2009;117:574-580.
11. Bandeen-Roche K, Glass TA, Bolla KI, Todd AC, Schwartz BS. Cumulative lead dose and cognitive function in older adults. Epidemiology 2009;20:831-839.
12. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004;19:1043-1049.
13. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958-2969.
14. Weisskopf MG, Weuve J, Nie H, et al. Association of cumulative lead exposure with Parkinson's disease. Environ Health Perspect 2010;118:1609-1613.
15. Coon S, Stark A, Peterson E, et al. Whole-body lifetime occupational lead exposure and risk of Parkinson's disease. Environ Health Perspect 2006;114:1872-1876.
16. Gorell JM, Johnson CC, Rybicki BA, et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997;48:650-658.
17. Adonaylo VN, Oteiza PI. Pb2+ promotes lipid oxidation and alterations in membrane physical properties. Toxicology 1999;132:19-32.
18. Acharya S, Acharya UR. In vivo lipid peroxidation responses of tissues in lead-treated Swiss mice. Ind Health 1997;35:542-544.
19. Ercal N, Treeratphan P, Hammond TC, Matthews RH, Grannemann NH, Spitz DR. In vivo indices of oxidative stress in lead-exposed C57BL/6 mice are reduced by treatment with meso-2, 3-dimercaptosuccinic acid or N-acetylcysteine. Free Radic Biol Med 1996;21:157-161.
20. Ercal N, Gurer-Orhan H, Aykin-Burns N. Toxic metals and oxidative stress part I: mechanisms involved in metal-induced oxidative damage. Curr Top Med Chem 2001;1:529-539.
21. White LD, Cory-Slechta DA, Gilbert ME, et al. New and evolving concepts in the neurotoxicology of lead. Toxicol Appl Pharmacol 2007;225:1-27.
22. Agency for Toxic Substances and Disease Registry. Toxicological Profile for Lead. Altanta, GA:Public Health Service, U.S. Department of Health and Human Services;2007.
23. Neal AP, Guilarte TR. Molecular neurobiology of lead (Pb(2+)): effects on synaptic function. Mol Neurobiol 2010;42:151-160.
24. Widzowski DV, Cory-Slechta DA. Homogeneity of regional brain lead concentrations. Neurotoxicology 1994;15:295-307.
25. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003;302:819-822.
26. Keane PC, Kurzawa M, Blain PG, Morris CM. Mitochondrial dysfunction in Parkinson's disease. Parkinsons Dis 2011;2011:716871.
27. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
28. Weuve J, Kang JH, Manson JE, Breteler MM, Ware JH, Grodstein F. Physical activity, including walking, and cognitive function in older women. JAMA 2004;292:1454-1461.
29. Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. Neuropsych Neuropsychol Behav Neurol 1988;1:111-117.
30. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
31. Goodglass H, Kaplan E. The Assessment of Aphasia. Philadelphia, PA:Lea & Febiger;1983.
32. Lezak MD. Orientiation and attention. In:Neuropsychological Assessment, 3rd ed.New York, NY:Oxford;1995:335-384.
33. Wilker E, Korrick S, Nie LH, et al. Longitudinal changes in bone lead levels: the VA Normative Aging Study. J Occup Environ Med 2011;53:850-855.
34. Aro AC, Todd AC, Amarasiriwardena C, Hu H. Improvements in the calibration of 109Cd K x-ray fluorescence systems for measuring bone lead in vivo. Phys Med Biol 1994;39:2263-2271.
35. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 2010;1184:188-195.
36. DeFries T, Avendano M, Glymour MM. Level and change in cognitive test scores predict risk of first stroke. J Am Geriatr Soc 2009;57:499-505.
37. Wadley VG, Unverzagt FW, McGuire LC, et al. Incident cognitive impairment is elevated in the stroke belt: the REGARDS study. Ann Neurol 2011;70:229-236.
38. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22:1689-1707; quiz, 1837.
39. Shih RA, Glass TA, Bandeen-Roche K, et al. Environmental lead exposure and cognitive function in community-dwelling older adults. Neurology 2006;67:1556-1562.
40. Invernizzi M, Carda S, Viscontini GS, Cisari C. Osteoporosis in Parkinson's disease. Parkinsonism Relat Disord 2009;15:339-346.
41. Adonaylo VN, Oteiza PI. Lead intoxication: antioxidant defenses and oxidative damage in rat brain. Toxicology 1999;135:77-85.